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ABSTRACT: Alzheimer’s disease (AD) is the most common
cause of adult dementia. Yet the complete set of molecular
changes accompanying this inexorable, neurodegenerative
disease remains elusive. Here we adopted an unbiased
lipidomics and metabolomics approach to surveying frozen
frontal cortex samples from clinically characterized AD patients
(n = 21) and age-matched controls (n = 19), revealing marked
molecular diﬀerences between them. Then, by means of
metabolomic pathway analysis, we incorporated the novel
molecular information into the known biochemical pathways
and compared it with the results of a metabolomics meta-
analysis of previously published AD research. We found six metabolic pathways of the central metabolism as well as
glycerophospholipid metabolism predominantly altered in AD brains. Using targeted metabolomics approaches and MS imaging,
we conﬁrmed a marked dysregulation of mitochondrial aspartate metabolism. The altered metabolic pathways were further
integrated with clinical data, showing various degrees of correlation with parameters of dementia and AD pathology. Our study
highlights speciﬁc, altered biochemical pathways in the brains of individuals with AD compared with those of control subjects,
emphasizing dysregulation of mitochondrial aspartate metabolism and supporting future venues of investigation.
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■ INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of adult-
onset dementia. Rising life expectancy is associated with
increased prevalence and incidence of dementia. A recent
report estimates that one in every three people born in the
United Kingdom in 2015 will suﬀer from this debilitating
mental illness during their lifetime.1 The need to identify novel
molecular targets for AD to use in diagnostics and therapeutics
is acute. Although a growing number of clinical research
laboratories use mass spectrometry (MS) applications to
investigate proteomic changes in AD,2−6 insuﬃcient eﬀort has
been dedicated to studying alterations in levels of small
molecules, metabolites, and lipids.2,7−9 To eﬀectively address
any therapeutic challenge in AD, however, requires detailed
information about its underlying molecular pathology.
Previous studies by our group and others have examined the
profound biochemical alterations in the AD brain.2,10−18 Most
of those studies adopted targeted analytical approaches that,
based on prior hypotheses, focused on a particular group of
lipids or metabolites, belonging, for example, to a speciﬁc
metabolic pathway. Changes in selected lipids or metabolites in
AD brains, it is speculated, result from a cascade of cellular
events involving abnormal β-amyloid protein metabolism, τ
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phosphorylation, oxidative stress, mitochondrial or peroxisomal
dysfunctions, inﬂammation, neurotransmitter changes, mem-
brane lipid dysregulation, apoptosis, or changes in other
proteins/chemicals.19,20 According to a targeted analytical
approach, however, the speciﬁc lipids or metabolites that
undergo analysis are selected according to the questions asked,
which might hinder the discovery of unexpected metabolic
dysregulations in AD brains.
The use of untargeted metabolomics and lipidomics
approaches, on the other hand, can oﬀer an unbiased view of
the molecular changes occurring in AD brains.21,22 Untargeted
approaches are hypothesis-generating and exploratory in nature,
their purpose being to obtain proﬁles of as many metabolites
and lipids as possible in biological samples. By comparing
metabolite and lipid proﬁles, we can thus determine patterns of
variations between control and AD subjects, and we can
generate novel hypotheses or support old venues of
investigations. According to an untargeted analytical approach,
features of interest are selected on the basis of statistical
analyses and are then identiﬁed and eventually quantiﬁed by
more targeted approaches. Yet most untargeted studies are
focused on biomarker discovery and usually provide only a list
of individual molecular species that are altered, while failing to
highlight the functional connectivity among diﬀerent bio-
chemical pathways in AD brains.
Recent technological advances in the ﬁeld of MS and
bioinformatics allows us to combine untargeted and targeted
analytical approaches in a single analysis to provide
simultaneously a bird’s-eye view of the interconnected
metabolic changes as well as a magniﬁed view of selected
biochemical pathways of interest, providing novel opportunities
to investigate AD brains. Furthermore, while traditional
approaches generally involve processing and extracting the
samples before MS analysis, which may alter the chemical
composition of the molecules under study, novel analytical
approaches such as MS imaging allow determination of the
spatial localization of lipids or metabolites in their natural
environment. By scanning through tissues, MS imaging allows
us to generate topographical maps of molecular distribution in
the AD brain.23,24
In this study, we used a combination of state-of-the-art
untargeted and targeted lipidomics and metabolomics, as well
as MS imaging, to proﬁle postmortem brains from AD subjects
and nondemented controls. Using innovative biostatistical and
bioinformatical approaches, we highlighted speciﬁc biochemical
pathways altered in AD, which were then correlated with
clinical records such as degrees of dementia and pathology.
Finally, we compared our results with a meta-analysis of
previously published research on AD, supporting venues of
investigations in AD research.
■ EXPERIMENTAL SECTION
Chemicals
All chemicals and polar metabolites used as standards were
purchased from Sigma−Aldrich (Seelze, Germany) and were of
analytical-grade purity or higher. Lipid standards were
purchased from Avanti Polar Lipids (Alabaster, AL) and
Cayman Chemicals (Ann Arbor, MI).
Tissue Procurement
From a cohort of 19 control subjects (12:7, males to females)
and 21 subjects with AD (9:12, males to females), frozen
human samples were obtained from the Banner Sun Health
Research Institute (Sun City, AZ) (Table 1). The samples were
matched for age: 83.5 ± 6.4 years for the control subjects and
82.4 ± 6.7 years for subjects with AD (mean ± standard
deviation, SD). The samples were also matched for
postmortem interval: 3.6 ± 1.7 h for control subjects and 3.6
± 1.4 h for subjects with AD (mean ± SD) (Table 1). AD cases
met the criteria of the National Institute on Aging−Reagan
Institute for intermediate or high likelihood of Alzheimer’s
disease. All subjects or, where appropriate, their caregivers
provided written, informed consent for the clinical examination
as well as for brain donation to the Banner Sun Health
Research Institute Brain and Body Donation Program. The
protocols and informed consent are approved by the Banner
Health Institutional Review Board.
Sample Preparation
Frozen brain samples were rapidly weighed (20 mg) and
homogenized in ice-cold methanol (1 vol) containing the
following internal standards: arachidonic acid-d8, cholesterol-d7,
C19:0-cholesteryl ester, trinonadecenoin, 1,2-dimyristoyl-sn-
glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-
phosphocholine, 1-heptadecenoyl-2-hydroxy-sn-glycero-3-phos-
phocholine, phenylalanine-d2, succinate-d4, [
13C6]glucose,
carnitine-d9, glutamic acid-d5, lysine-d4, alanine-d4, and
[13C10,
15N5]AMP. Metabolites were extracted by adding
chloroform and water (2:1 v/v) and centrifuged at 10000g
for 10 min at 4 °C. The bottom phases (mostly lipids) were
dried under nitrogen, reconstituted in 2-propanol/acetonitrile/
water (4:3:1 v/v/v, 0.1 mL) and subjected to liquid
chromatography−masss spectrometry (LC−MS) analysis. The
upper phases (polar metabolites) were dried under vacuum,
reconstituted in water/acetonitrile (1:1 v/v, 0.2 mL), and
subjected to LC−MS analysis. A small amount (10 μL) from
each sample was pooled, for use as quality controls for LC−MS
analyses.
Metabolomic Analyses
Chromatographic separation was achieved by use of an Acquity
ultraperformance liquid chromatography (UPLC) system
(Waters Corporation, Milford, MA) and hydrophilic-interac-
tion liquid chromatography (HILIC) using a 1.7 μm (2.1 × 150
mm) Acquity amide column (Waters).25−27 A Synapt G2 mass
spectrometer (Waters) was coupled with the UPLC system and
operated in data-independent mode (MSE).28 Pooled samples
were analyzed in high-deﬁnition MSE mode (HDMSE).23,29 In
positive electrospray mode, the capillary and cone voltage were
1.5 kV and 30 V, respectively. The source and desolvation
temperatures were 120 and 500 °C, respectively, and the ﬂow
rate of desolvation gas was 800 L/h. During MSE experiments,
the collision energy in the trap cell was 4 eV (function 1), and
in the transfer cell, it ranged from 15 to 30 eV (function 2).
Samples were analyzed three times by UPLC−HILIC−MSE,
once in positive ionization mode and twice in negative
ionization mode, under acidic and basic chromatographic
conditions, respectively.25,30 In positive mode and in negative
acidic conditions, mobile phase A was 100% acetonitrile and
mobile phase B was 100% H2O, with both containing 0.1%
formic acid. The following elution gradient was used: 0 min,
99% A; 6 min, 40% A; 8 min, 99% A; 10 min, 99% A. In
negative-mode basic conditions, mobile phase A contained
acetonitrile/sodium bicarbonate, 10 mM (95:5), and mobile
phase B contained acetonitrile/sodium bicarbonate, 10 mM
(5:95). The following elution gradient was used: 0 min, 99% A;
5 min, 42% A; 6 min, 70% A; 7 min, 99%; 10 min, 99% A. In all
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conditions, the ﬂow rate was 0.4 mL/min, the column
temperature was 45 °C, and the injection volume was 3.5 μL.
Lipidomic Analyses
Lipidomic analyses of the brain samples were performed by use
of an ionKey/MS system composed of the Acquity UPLC M-
Class, ionKey source, and an iKey CSH C18 130 Å (1.7 μm
particle size) 150 μm × 100 mm column (Waters) coupled to a
Synapt G2-Si (Waters). Analyses were conducted with both
positive and negative electrospray in MSE mode. Pooled
samples were analyzed in high-deﬁnition MSE mode
(HDMSE).23,24,31 The capillary voltage was 2.8 kV and the
source temperature was 110 °C. Injections were 0.5 μL in the
partial-loop mode, with a column temperature of 55 °C and
ﬂow rate of 3 μL/min. Mobile phase A consisted of
acetonitrile/water (60:40) with 10 mM ammonium formate +
0.1% formic acid. Mobile phase B consisted of 2-propanol/
acetonitrile (90:10) with 10 mM ammonium formate + 0.1%
formic acid. The gradient was programmed as follows: 0.0−2.0
min, from 40% to 43% B; 2.0−2.1 min, to 50% B; 2.1−12.0
min, to 99% B; 12.0−12.1 min, to 40% B; and 12.1−14.0 min,
at 40% B.
Laser Ablation Electrospray Ionization Mass Spectrometric
Imaging
Frozen human brain samples were serially sectioned in a
cryostat, to allow alternate microscopic and MS-imaging
analyses. Sections were placed on standard microscope slides
and kept frozen at −15 °C throughout the analysis using the
Peltier cooling stage of laser ablation electrospray ionization
(LAESI). Sections were analyzed on a LAESI DP-1000 Direct
Ionization System (Protea Bioscience, Morgantown, WV)
coupled with a Synapt G2-S mass spectrometer operated in
HDMS mode. The electrospray solution for LAESI was
methanol/water (50:50 v/v) with 0.1% acetic acid. LAESI
parameters consisted of 10 laser pulses/pixel, at 5 Hz and 800
μJ laser energy. Data were collected in both negative- and
positive-ion modes with a mass range of m/z 50−1500 for MS
scans as well as for ion mobility−MS scans. Identiﬁcations were
made according to accurate mass and collision cross sections
(CCS) values.29 Selected drift-time regions were extracted by
use of DriftScope software (Waters). Ion distribution maps
were created for mass values of interest by use of ProteaPlot
v2.0.3.8 (Protea Bioscience).
Data Processing and Analysis
Data processing and analysis was conducted by use of
Progenesis QI Informatics (Nonlinear Dynamics, Newcastle,
U.K.).29 Each UPLC−MS run was imported as an ion-intensity
map, including m/z and retention time. These ion maps were
then aligned in the retention-time direction. From the aligned
runs, an aggregate run representing the compounds in all
samples was used for peak picking. This aggregate was then
compared with all runs, to ensure that the same ions are
detected in every run. Isotope and adduct deconvolution was
applied, to reduce the number of features detected. Data were
normalized according to total ion intensity. A combination of
analysis of variance (ANOVA) and multivariate statistics,
including principal-component analysis (PCA) and orthogonal
partial least-squares discriminant analysis (OPLS-DA), identi-
ﬁed features most responsible for diﬀerences between sample
groups. Before multivariate analysis, data were scaled by Pareto
and log-transformed. PCA and OPLS-DA were performed with
SIMCA-P (Umetrics, Umea, Sweden), Metabolites were
identiﬁed by database searches against their accurate masses
in publicly available databases, including the LIPID MAPS32
database and the Human Metabolome database (HMDB),33 as
well as by fragmentation patterns, retention times, and CCS
values, when available. Pathway analysis, which consisted of
enrichment analysis and pathway topological analysis, were
conducted with the Metabolomics Pathway Analysis (MetPA)
feature within MetaboAnalyst.34 TargetLynx software (Waters)
was used for targeted analysis of selected features with internal
standards for each class as previously reported.25,30 Correlation
analysis was performed by MetaboAnalyst.34 Pearson test (r)
was used to measure the correlation.
Metabolite Cluster Enrichment Analysis
Enrichment analysis of changed metabolite classes, subclasses,
and LIPID MAPS32 subclasses was performed according to the
methods previously used by Watschinger et al.,35 with some
modiﬁcations. Brieﬂy, a distance matrix between metabolite
proﬁles was generated by hierarchical clustering of normalized
proﬁles (Z-scores) and then used to separate the metabolites
into six clusters, according to their similarities. For each cluster,
HMDB33 class, HMDB subclass, and LIPID MAPS32 subclass
enrichment analysis was performed separately. Depending on
the level on which the enrichment analysis was performed, all
annotated IDs from the respective databases were used. For
each individual HMDB class, HMDB subclass, and LIPID
MAPS subclass, a hypergeometric test based on the counts of
signiﬁcantly altered compounds versus all possible identiﬁca-
tions was performed. We selected an ANOVA p-value of 0.01
and a minimum number of three or more compounds per
category as signiﬁcance criteria. Every enrichment analysis was
performed separately for the complete data set as well as for all
six clusters identiﬁed on the basis of proﬁle similarity (as
described above).
Metabolomics Pathway Meta-Analysis
The PubMed database was cross-searched (in March 2015) for
the term “Alzheimer” and each metabolite present in the
HMDB in all ﬁelds (i.e., title, abstract, keywords). Information
about the human metabolome was downloaded from the
HMDB at the Web address www.hmdb.ca/download. Each
metabolite entry was saved as an extensible markup language
(XML) ﬁle called MetaboCard. Each MetaboCard entry
contains more than 110 data ﬁelds, with two-thirds of the
information devoted to chemical and physical data and the
remaining third to enzymatic or biochemical data. Many data
ﬁelds are linked to other databases (KEGG, PubChem,
MetaCyc, ChEBI, PDB, UniProt, and GenBank).33,36,37 R
software,38 running on scripts developed in-house, was used to
gain access to the MetaboCard entries, to obtain information
about each metabolite and its synonyms, and to query the
PubMed database in all ﬁelds (i.e., title, abstract, keywords).
Because in the literature the same metabolite can be present
under diﬀerent names, each query to PubMed was parsed as
follows: “Alzheimer AND (synonym#1 OR synonym#2 OR
synonym#3 OR synonym#4)”. The functions xmlTreeParse
and xmlValue of the R-package XML were used to analyze the
output from PubMed and to count the numbers of papers for
each query. A metabolite-set enrichment analysis (MSEA) was
performed by over-representation analysis (ORA) using the
Web tool freely available at the Internet address http://www.
msea.ca/MSEA/.
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■ RESULTS
Table 1 shows the demographic and neuropathological
characteristics of the subjects with AD and the control subjects
used in this study. Notably, in order to limit artifacts due to
aging or tissue degradation, the groups were closely matched
for age and postmortem interval, which on average was kept
under 4 h.
Unbiased Metabolomic and Lipidomic Analyses
To extract metabolites and lipids from the same brain tissue
samples, we used a biphasic liquid/liquid extraction method.
The procedure permitted the extraction of selectively polar
metabolites in the aqueous phase while lipids were isolated in
the organic phase. We then applied, separately, our untargeted
metabolomic and lipidomic workﬂows to these samples.
Additional brain samples were also prepared for MS imaging
analyses (Figure 1).
To determine whether the disease induced molecular
diﬀerences in AD brains, we ﬁrst used multivariate statistical
approaches as an initial step for data visualization. PCA and
OPLS-DA showed clear clustering of the control and AD brains
for both lipidomic (Figure S1a, Supporting Information) and
metabolomic (Figure S1b, Supporting Information) analyses.
Integration of lipidomic and metabolomic information showed
that 82% of metabolite alterations presented joint variations
with lipids, whereas 20% of the lipids evidenced unique
variations (Figure S1c, Supporting Information). These
observations indicate that AD brains sustained profound
molecular changes that aﬀected both lipids and other metabolic
pathways in an interconnected fashion.
Enrichment Analyses
To determine the chemical classes of lipids and metabolites
altered in AD brains, we performed a hierarchical clustering
analysis of all the potential molecular identiﬁcations (Figure
2A). Metabolites could be divided into six clusters, according to
the distance between their individual proﬁles (Figure 2). Three
of the clusters (1, 3, and 4) were characterized by a signiﬁcant
increase in metabolite levels in AD samples, compared with
nondemented (ND) controls (Figure 2a). The remaining three
clusters (2, 5, and 6) revealed the opposite eﬀect: higher levels
of metabolites in the controls (Figure 2A).
Although the apparent diﬀerences between clusters with
similar proﬁle changes are small, our enrichment analysis
revealed that the clusters have distinct metabolic compositions
(Figure 2B,C). The HMDB classiﬁcation system allowed us to
diﬀerentiate metabolites according to their kingdom, superclass,
class, and subclass (Figure 2B). The LIPID MAPS classiﬁcation
system provided additional information. Located one layer
below the HMDB subclass information, the LIPID MAPS
subclass information, with an associated LIPID MAPS ID, was
also included in the analysis for metabolites (Figure 2C). This
analysis indicated that the lipid class of glycerophospholipids
in particular, phosphatidylcholines and phosphatidylethanol-
aminesappeared to be mostly altered in AD brains, compared
with control brains, a ﬁnding cited in previous reports.10,20,39−47
It is important to note that the same class of metabolites, such
as glycerophospholipids, showed an increase in AD in clusters
1−3 but a decrease in clusters 4 and 5 (Figure 2B), which
indicates diﬀerential regulation of lipid species within the same
subclass (Figure 2C). Changes in lipid composition may
profoundly aﬀect membrane structure, transmembrane signal-
ing, and cell-to-cell communication in the brain, and they may
thus underlie an important aspect of AD pathology. Further
studies will aim to validate such lipid variations and their
relationship to AD.
Alterations in Metabolic Pathways
To determine the biochemical pathways mostly aﬀected in AD
brains, we identiﬁed and monitored by a targeted approach25 a
subset of polar metabolite that was shown to discriminate
between brains from AD patients and those from ND controls
(Figure 3a,b). Metabolites were identiﬁed from an in-house
database24,25,29 and, where standards were not available, by
comparing exact mass and fragmentation spectra information
with online databases. Metabolomics pathway analysis indicated
Table 1. Demographic and Neuropathological Features of
Subjects in This Studya
AD subjects control subjects
total number 21 19
sex (male/female) 9/12 12/7
age, years 82.4 ± 6.7 83.5 ± 6.4
postmortem interval,
hours
3.6 ± 1.4 3.6 ± 1.7
tangle score (Braak
and Braak)
V (n = 11); VI
(n = 10)
I (n = 2); II (n = 4); III (n = 7);
IV (n = 6);
plaque density frequent (20);
Moderate (1)
zero (7); sparse (2); moderate
(4); frequent (6)
MMSE score 13.4 ± 7.9 28.0 ± 1.7
BMI 24.7 ± 3.8 25.0 ± 3.9
aPlus and minus values are means ± SD. BMI, body-mass index;
MMSE, mini-mental status examination.
Figure 1. Experimental workﬂow. Frontal cortex samples from AD
subjects (n = 21) and nondemented controls (n = 19) were extracted
via a biphasic system (CHCl3/CH3OH/H2O, 2:1:1 v/v/v). Top layer
was analyzed by a metabolomics approach for polar metabolites;
bottom layer was analyzed by a lipidomics approach for lipids. Initial
discovery data were further investigated by targeted metabolic-
proﬁling approaches and MS imaging. The results were then fused
and integrated with clinical parameters.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.5b01020
J. Proteome Res. 2016, 15, 608−618
611
six metabolic pathways aﬀected during AD (Figure 3c,d and
Table 2). In particular, alanine, aspartate, and glutamate
metabolism proved one of the most aﬀected pathways in the
frontal cortices of subjects with AD, compared with those of
nondemented control subjects (Figure 3c,d and Table 2).
A signiﬁcant dysregulation of aspartate and glutamate
metabolism was also conﬁrmed by the MS imaging experiment
(Figure 4b). Alterations of metabolites such as aspartate,
glutamate, citrate, and malate (Figure 4a) as well as
accumulation of N-acetylaspartate (NAA) (Figure 4b) and
pyruvate, serine, and lactate (Figure S2, Supporting Informa-
tion), in the frontal cortex samples of the AD subjects suggest
that the transport mechanism between mitochondria and
cytosol might be impaired in AD brains (Figure 4c).
To determine the clinical signiﬁcance of these metabolomic
ﬁndings, we created scores indicative of the levels of
metabolites belonging to the six metabolic pathways (Table
2) and correlated them with parameters of dementia and AD
pathology (Figure 3b,d). For each pathway a PLS model was
built considering the metabolite concentrations as X and the
metadata as y. A permutation test on y and a stability test based
on Monte Carlo sampling and PLS VIP-based were performed
to check overﬁtting. The set of metabolites detected by stability
test was used to calculate Q2CV,7‑fold (i.e., R
2 calculated by 7-fold,
full, cross-validation). Robust models for all pathways were
found for AD, with the alanine, aspartate, and glutamate
pathway having the strongest correlation. No associations with
age, postmortem interval (PMI), body mass index (BMI), and
gender (Figure 3b,d) were found, with the only exception being
a minor association between pathway 5 and gender (Figure 3
d). All the pathways were strongly associated with pathological
hallmarks of AD, such as tangles, while a smaller association
was found with plaques. One of the most promising models for
explaining cognitive status as measured by mini-mental state
examination (MMSE) was found for metabolites of the alanine,
aspartate, and glutamate pathway.
An in-depth analysis of the alanine, aspartate, and glutamate
pathway revealed that the levels of aspartic acid and succinic
acid positively correlated with MMSE, whereas the levels of
pyruvic acid, glutamine, and NAA negatively correlated with
MMSE (Figure S3, Supporting Information). Levels of alanine,
asparagine, and glutamic acid showed only a weak correlation
with the clinical data (Figure S3, Supporting Information).
Literature Comparison
To compare our results with the literature, we performed a
metabolomics meta-analysis of the previously published AD
literature in PubMed. We cross-searched the terms “Alzheimer”
and the complete list of metabolites and their synonyms, as
Figure 2.Metabolite cluster and enrichment analysis of molecular species aﬀected by AD. (A) Unsupervised hierarchical clustering analysis of all the
potential molecular identiﬁcations according to their coregulation in AD brains. The clustered proﬁles were divided into six diﬀerent groups with
distinctive behavior. Metabolite and lipid concentration changes are shown in the respective groups. Each box is calculated from all lipids belonging
to the respective group, each with peak-area data from ﬁve biological replicates. Z scores were determined according to the mean and SD of all data
for the respective metabolite. (B) Enrichment analysis obtained by use of the HMDB classiﬁcation system. (C) Lipid subclass enrichment analysis
obtained by use of the LIPID MAPS classiﬁcation system. Only signiﬁcantly enriched subclasses for AGMO modulation are shown (P-value of
enrichment <0.001). Circle size represents the number of lipid species matching the respective subclass. Enrichment P-values are indicated by the
intensity of coloration of the circles.
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reported in HMDB (41 514 entries).33 We then used the
number of publications as an index of correlation between AD
and the metabolite. A metabolite-set enrichment analysis37
helped identify patterns of metabolites most studied in AD
research. It showed the aspartate and glutamate pathway as
historically one of the most studied, agreeing with the outcome
of our metabolomics investigation (Figure S4, Supporting
Information).
■ DISCUSSION
In this study we used a combination of innovative analytical
approaches to conduct an unbiased metabolomics and
lipidomics investigation of the biochemical pathways that are
aﬀected in AD brains.
As for all metabolomics and lipidomics analyses, study
design, such as sample size, postmortem interval, and genotype
(e.g., ApoE), as well as standard operating procedures, such as
sample preparation, can aﬀect results. Our study had multiple
key features in terms of the analytical aspects that should be
taken into consideration. First, our cohort size was of 21 AD
subjects and 19 nondemented controls; groups were matched
by age and postmortem interval, and frontal cortices were
selected as region of the brain. Second, in order to limit artifacts
due to sample degradation, our criteria for subject selection
required a postmortem interval average of less than 4 h, which
is remarkably short for postmortem brains. Third, to further
limit artifacts due to enzymatic reactions and oxidation, brain
samples were weighed while still frozen and then they were
quenched with ice-cold methanol. Liquid/liquid extraction
allowed us to separate hydrophilic from hydrophobic
compounds in a single procedure, and MS imaging was also
used to support and conﬁrm traditional analyses while avoiding
the process of extracting the samples. Finally, using data-
independent acquisition mode, we obviated the need to analyze
the sample in untargeted MS mode and then rerun the same
sample in targeted MS/MS mode, but instead we automatically
acquired the fragmentation data from each precursor ion.48 The
simultaneous generation of high-resolution, full-scan, and
fragmentation spectra served as a repository of biological
information that was reused after statistical analyses to
semiquantify selected biochemical pathways. This approach
allowed us to combine untargeted and targeted analysis,
maximizing the identiﬁcation of compounds and biochemical
pathways in a single analytical run.
Our study uncovered signiﬁcant alterations in key mitochon-
drial metabolites, which correlated with symptoms of dementia
and AD pathology. Notably, as highlighted from our literature
meta-analysis, previous research on AD largely focused on
targeted metabolites of the alanine, aspartate, and glutamate
metabolism, often missing a bird’s-eye view of the underlying
Figure 3. Integration of metabolomics and clinical information. (a) Heat map of selected polar metabolites. (b) Principal component analysis
performed on clinical information. (c) Pathway analysis performed on metabolomics results. (d) Integration of pathway analysis results with clinical
information. The heat map shows the relationships between clinical data and pathways. Pathways and metadata are ordered according to hierarchical
cluster analysis, to simplify interpretation of the map. Metadata close to each other have a similar proﬁle with respect to relationships with the
pathways, while pathways close to each other show similar relationships with respect to the metadata; here “relationships” means linear relationships
between the concentrations of the metabolites included in the pathway and the metadata on the basis of PLS regression. The heat map was colored
according to Q2CV,7‑fold. NS means no signiﬁcant PLS regression model (Q
2
CV,7‑fold p-value > 0.05).
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biochemical alterations and their functional metabolic con-
nectivity. Our metabolomic approach provided a comprehen-
sive view of key metabolites of this pathway, pointing to a
speciﬁc mitochondrial dysfunction in AD brains, which aﬀects
processes involved in the transport of metabolites between
mitochondria and cytosol.
Table 2. List of Most Aﬀected Pathways and Their Metabolites in Human Frontal Cortex of AD Subjects Compared to ND
Control Subjectsa
HMDB ID metabolite AD ND t-test p-value
Path 1: Alanine, Aspartate, and Glutamate Metabolism (p = 7.19 × 10−9)
HMDB00812 acetylaspartic acid 1.01 ± 0.44 0.57 ± 0.21 2.47 × 10−4
HMDB00191 aspartic acid 1.50 ± 0.78 3.37 ± 1.33 2.67 × 10−6
HMDB00161 alanine 5.95 ± 1.68 5.28 ± 1.07 1.45 × 10−1
HMDB00168 asparagine 0.15 ± 0.07 0.20 ± 0.09 1.07 × 10−1
HMDB00243 pyruvate 0.09 ± 0.03 0.05 ± 0.03 6.11 × 10−5
HMDB00148 glutamic acid 24.43 ± 8.58 18.31 ± 7.06 1.92 × 10−2
HMDB00641 glutamine 43.09 ± 24.72 16.92 ± 10.70 1.28 × 10−4
HMDB00254 succinic acid 0.20 ± 0.07 0.21 ± 0.10 5.47 × 10−1
Path 2: Arginine and Proline Metabolism (p = 1.58 × 10−8)
HMDB00191 aspartic acid 1.50 ± 0.78 3.37 ± 1.33 2.67 × 10−6
HMDB00641 glutamine 43.09 ± 24.72 16.92 ± 10.70 1.28 × 10−4
HMDB00148 glutamic acid 24.43 ± 8.58 18.31 ± 7.06 1.92 × 10−2
HMDB00517 arginine 12.92 ± 6.00 10.34 ± 3.81 1.17 × 10−1
HMDB00162 proline 0.17 ± 0.08 0.13 ± 0.06 6.69 × 10−2
HMDB01185 SAMe 2.03 ± 0.80 1.38 ± 0.83 1.69 × 10−2
HMDB00725 hydroxyproline 3.21 ± 2.02 1.42 ± 0.85 9.91 × 10−4
HMDB00243 pyruvate 0.09 ± 0.03 0.05 ± 0.03 6.11 × 10−5
HMDB01138 acetylglutamic acid 17.77 ± 8.12 9.81 ± 3.66 3.52 × 10−4
Path 3: Cysteine and Methionine Metabolism (p = 1.81 × 10−7)
HMDB00191 aspartic acid 1.50 ± 0.78 3.37 ± 1.33 2.67 × 10−6
HMDB00187 serine 2.67 ± 1.61 1.54 ± 0.66 7.31 × 10−3
HMDB00192 cystine 0.197 ± 0.200 0.20 ± 0.20 9.64 × 10−1
HMDB00161 alanine 5.95 ± 1.68 5.28 ± 1.07 1.45 × 10−1
HMDB00696 methionine 0.69 ± 0.24 0.58 ± 0.26 1.59 × 10−1
HMDB00939 SAH 0.82 ± 0.29 0.62 ± 0.22 2.26 × 10−2
HMDB01185 SAMe 2.03 ± 0.80 1.38 ± 0.83 1.69 × 10−2
HMDB00243 pyruvate 0.09 ± 0.03 0.05 ± 0.03 6.11 × 10−5
Path 4: Glycine, Serine, and Threonine Metabolism (p = 1.01 × 10−8)
HMDB00191 aspartic acid 1.50 ± 0.78 3.37 ± 1.33 2.67 × 10−6
HMDB00167 threonine 1.52 ± 1.70 0.31 ± 0.21 3.86 × 10−3
HMDB00187 serine 2.67 ± 1.61 1.54 ± 0.66 7.31 × 10−3
HMDB00097 choline 0.59 ± 0.26 0.41 ± 0.24 2.73 × 10−2
HMDB00929 tryptophan 0.12 ± 0.06 0.10 ± 0.04 3.29 × 10−1
HMDB00243 pyruvate 0.09 ± 0.03 0.05 ± 0.03 6.11 × 10−5
Path 5: Purine Metabolism (p = 3.13 × 10−6)
HMDB00618 pentose 5-phosphate 0.011 ± 0.005 0.009 ± 0.005 2.87 × 10−1
HMDB01178 ADP-ribose 0.09 ± 0.07 0.06 ± 0.06 1.52 × 10−1
HMDB00641 glutamine 43.09 ± 24.72 16.92 ± 10.70 1.28 × 10−4
HMDB01341 ADP 0.016 ± 0.013 0.010 ± 0.010 1.45 × 10−1
HMDB00045 AMP 0.32 ± 0.26 0.19 ± 0.22 8.95 × 10−2
HMDB01397 GMP 0.07 ± 0.04 0.06 ± 0.05 2.97 × 10−1
HMDB00133 guanosine 2.35 ± 1.84 2.35 ± 2.04 9.99 × 10−1
HMDB00175 IMP 0.02 ± 0.01 0.01 ± 0.01 2.70 × 10−2
HMDB00289 uric acid 0.80 ± 0.43 1.10 ± 0.65 8.90 × 10−2
HMDB00292 xanthine 1.09 ± 0.47 2.29 ± 1.08 4.10 × 10−5
HMDB00299 xanthosine 0.09 ± 0.04 0.20 ± 0.13 9.03 × 10−4
HMDB00157 hypoxanthine 25.91 ± 9.08 22.68 ± 9.34 2.74 × 10−1
HMDB00195 inosine 23.76 ± 11.38 36.80 ± 17.68 7.95 × 10−3
Path 6: Pantothenate and CoA Biosynthesis (p = 1.49 × 10−08)
HMDB00191 aspartic acid 1.50 ± 0.78 3.37 ± 1.33 2.67 × 10−6
HMDB00243 pyruvate 0.09 ± 0.03 0.05 ± 0.03 6.11 × 10−5
HMDB00883 valine 0.09 ± 0.03 0.08 ± 0.03 5.21 × 10−1
HMDB00210 pantothenic acid 2.19 ± 2.18 1.82 ± 0.61 4.77 × 10−1
aValues are expressed as means ± SD of normalized MS intensity. HMDB, Human Metabolome Database.
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Acetyl-CoA can be transported into mitochondria by means
of two main shuttles after conversion into either NAA or citrate
(Figure 4c). In the ﬁrst mitochondrial shuttle, NAA is
transported into the mitochondria, then converted to acetate
by aspartoylacylase, and ﬁnally converted back to acetyl-CoA by
acetyl-CoA synthetase (Figure 4c). The observation that levels
of key metabolites in this process (i.e., NAA, aspartate, and
glutamate) are altered in AD and correlated with dementia and
pathology suggests that this transport mechanism is aﬀected in
AD (Figure 4). In the second mitochondrial shuttle, citrate is
transported into the mitochondria and then converted back
into acetyl-CoA by ATP-citrate lyase. The observation that
levels of key metabolites in this process (i.e., citrate, malate,
glutamate, and aspartate) were signiﬁcantly changed in AD
supports an impairment in the transport mechanism. The fact
that key metabolites in both mitochondrial shuttles are altered
could reﬂect a more general mitochondrial dysfunction in AD
brains.
The role of mitochondria as regulators of brain energy
metabolism makes it crucial to neuronal cell survival or death.
Growing evidence indicates that mitochondrial dysfunction is
an early event during the progression of AD and one of the key
intracellular mechanisms associated with the pathogenesis of
this disease.49−52 Recent ﬁndings demonstrated that α-
ketoglutarate dehydrogenase complex regulates mitochondrial
metabolism through post-translational modiﬁcation of other
enzymes in mitochondria53 and that AD patients have
decreased activity of this enzyme.54
Our observations agree with a recent report that was 1H
NMR-based.55 Altered concentrations of brain NAA, as
measured by magnetic resonance (MR), have been commonly
associated with neurotoxicity, and its levels have been used to
assess in vivo neuronal loss and neurodegeneration in AD.56−58
However, NAA concentration in the brain varies according to
the brain region investigated. Indeed, it has been shown that
the concentration of NAA selectively decreases in speciﬁc brain
areas such as the hippocampus and amygdala but not in the
frontal cortex.59
We cannot exclude that the levels of NAA and other
metabolites are a consequence of dietary regimens or
pharmacological treatments of the AD subjects. Previous
evidence indicates, for example, that levels of NAA increase
during cholinergic treatment in AD60,61 and could be reversed
after other therapeutic interventions.62,63 Further investigations
are needed to better understand the role of mitochondrial
aspartate metabolism in AD.
■ CONCLUSIONS
AD is a neurodegenerative disorder characterized by the loss of
cognitive abilities and the appearance of pathological hallmarks
in the brain, such as extraneuronal plaques and neuroﬁbrillary
tangles. In this study, we used an innovative analytical approach
based on a combination of untargeted and targeted lipidomic
and metabolomics, as well as MS imaging, to investigate
metabolic alterations occurring in the AD brain. We explored
the biochemical signiﬁcance of observed metabolic alterations
according to known metabolic pathways. We then used novel
bioinformatics and biostatistical approaches to integrate the
novel acquired metabolic knowledge of AD brains with clinical
records and literature metadata. Most notably, we uncovered a
signiﬁcant dysregulation in mitochondrial aspartate metabolism
in the AD brain, which correlated with dementia and AD
pathology. As such, our study provides a solid rationale for
future pharmacological or metabolic interventions and other
functional experiments aimed to better understand the role
played by mitochondrial aspartate metabolism in the etiology
and progression of the cognitive impairment and pathological
hallmarks associated with AD. Our study also suggests novel
venues of investigation for biomarker discovery in peripheral
tissues, such as blood, related to the metabolic changes that we
observed in AD brains.
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